

*The Relation between serum Omentin and insulin
resistance in Gestational diabetes*

THESIS

Submitted for partial fulfillment of Master Degree in Internal Medicine

Presented by

Eman Ibrahim Yones

(M.B., B. Ch.)

Faculty of Medicine - Ain Shams University

Under supervision of

Prof. Salah El-Din Ahmed shelbaya

Professor of Internal Medicine, And Endocrinology

Faculty of Medicine - Ain Shams University

Dr. Rana Hashem Ibrahim El Attary

Lecturer of Internal Medicine, And Endocrinology

Faculty of Medicine - Ain Shams University

Dr. Salah Hussein Aly Elhalawany

Lecturer of Internal Medicine, And Endocrinology

Faculty of Medicine - Ain Shams University

Faculty of Medicine

Ain shams

(2019)



*First I would like to thank **Allah** the compassionate and merciful, for his great help and support during this work whose help is the main factor in accomplishing this work.*

*Also I would like to express my deep gratitude to **Prof. DR; Salah El-Din Ahmed shelbaya** Professor of Internal Medicine, And Endocrinology, Faculty of Medicine, Ain Shams University for his constructive guidance, remarkable effort, scientific assistance, encouragement and supervision through my work.*

*Also I would like to express my thanks and great appreciation to **DR; Rana Hashem Ibrahim El Attary** lecturer of Internal Medicine, And Endocrinology, Faculty of Medicine, Ain Shams University for her great help and kind advice on my thesis.*

*Also I would like to express my thanks and great appreciation to **Dr. Salah Hussein Aly Elhalawany** lecturer of Internal Medicine, And Endocrinology, Faculty of Medicine, and Ain Shams University for his great help and effort to provide me with his valuable advice on my thesis.*

Contents

INTRODUCTION	1
Aim of the work	3
Gestational Diabetes	4
Incidence and prevalence	11
Risk factors	11
How to screen for Gestational Diabetes.....	12
Screening Methods.....	13
Complications	14
Management.....	16
Omentin.....	24
Discovery	24
Genetic Control.....	24
Structure.....	24
Binding Ligands.....	25
Distribution of Omentin.....	25
Physiological Role of Omentin.....	26
Clinical Significance of Omentin.....	27
Relation between serum omentin and gestational diabetes.....	35
Placenta and maternal adipose tissue omentin-1 expression and release.	37
Association of serum omentin-1 concentrations with the presence and severity of preeclampsia	39
Methods of Assay of Omentin	40
PATIENTS AND METHODS.....	44
Data management and statistical analysis.....	50
Results.....	53
Discussion	83
Summary	89
Conclusion	92
RECOMMENDATION	93
REFERENCES	94

LIST OF TABLES

Table (1): Recommended Glycemic Targets for Patients with Gestational Diabetes	16
Table (2): Recommendations for Weight Gain and Caloric Requirements During Pregnancy....	17
Table (3): Insulin Preparations Used in the Management of Gestational Diabetes	19
Table (4): Descriptive data of all the studied groups	58
Table (5): Comparison between three studied groups regarding omentin, Insulin level (fasting) and HOMA IR, Fasting blood glucose, blood glucose at (30, 60, 90 and 120 min) and lipid profile.....	59
Table (6): Descriptive data of subjects with insulin resistance (HOMA>2.7) and with insulin resistance (HOMA<2.7).....	64
Table (7): Correlation between omentin as regards insulin level, fasting blood glucose and lipid profile in Group I and Group II.....	68
(Table 8): Linear regression (association between OMENTIN and HOMA IR).....	75
Table (9): ROC curve analysis for the diagnostic value of OMENTIN in discrimination between subjects with or without insulin resistance.	76
Table (10): ROC curve analysis for the diagnostic value of HOMA IR in discrimination between subjects with or without insulin resistance.	77

LIST OF FIGURES

Figure (1): Classification of diabetes in pregnancy.	5
Figure (2): Summary of potential mechanisms for insulin resistance in skeletal muscle during late pregnancy in human gestational diabetes.....	9
Figure (3): Risk factors for the GDM development.....	12
Figure (4): Screening and diagnostic criteria for gestational diabetes mellitus.....	14
Figure (5): Omentin vascular action. The antiangiogenic effect of omentin by inhibiting Akt and NF- κ B pathways, important regulators of inflammation, and angiogenesis. Omentin causes vasodilatation by increasing nitric oxide production via endothelial nitric oxide synthase (Tan et al., 2010).	26
Figure (6): A graphical pathway analysis of the protective effects of omentin-1 against IL-1b induced cartilage matrix destruction.	31
Figure (7): Fat-derived adipokine omentin-1 serves as a novel marker for cardiovascular and non-cardiovascular diseases and acts as a key mediator of the protective actions to various stresses.	34
Figure (8): Localisation of omentin-1 in human placenta.	38
Figure (9): The principle of ELISA	41
Figure (10): Omentin regarding studied groups.....	61
Figure (11): HOMA IR regarding studied groups	62
Figure (12): Insulin level regarding studied groups.....	62
Figure (13): Fasting blood glucose, blood glucose after (30, 60, 90 and 120 min) regarding studied groups.	63
Figure (14): Lipid profile regarding studied groups.	63
Figure (15): Omentin as regards HOMA.....	64
Figure (16): Insulin as regards HOMA.....	65
Figure (17): fasting blood glucose as regards HOMA.....	66
Figure (18): Lipid profile as regards HOMA.....	67
Figure (19): Insulin level regarding omentin in gestational diabetes.	68
Figure (20): Fasting blood glucose regarding omentin in gestational diabetes.	69
Figure (21): Cholesterol regarding omentin in gestational diabetes.	69
Figure (22): Triglyceride regarding omentin in gestational diabetes.....	70
Figure (23): HDL regarding omentin in gestational diabetes.	70
Figure (24): LDL regarding omentin in gestational diabetes.....	71
Figure (25): Insulin regarding omentin in normal glucose tolerance	71
Figure (26): Fasting blood glucose regarding omentin in normal glucose tolerance.	72
Figure (27): Cholesterol regarding omentin in normal glucose tolerance	72
Figure (28): Triglyceride regarding omentin in normal glucose tolerance.....	73
Figure (29): HDL regarding omentin in normal glucose tolerance	73
Figure (30): LDL regarding omentin in normal glucose tolerance.....	74
Figure (31): Spearman correlation show negative significant correlation between OMENTIN and HOMA IR (p <0.05)	75
Figure (32): ROC curve for discrimination between subjects with or without insulin resistance using serum OMENTIN.....	76
Figure (33): ROC curve for discrimination between subjects with or without insulin resistance using serum HOMA IR.	77

LIST OF ABBREVIATIONS

ACOG	American College of Obstetricians and Gynecologists
ADA	American Dental Association
ADAMTS	A Disintegrin and Metalloproteinase with Thrombospondin motifs
Akt	Protein kinase B (PKB)
AMPK	5' adenosine monophosphate-activated protein kinase is an enzyme
BMI	Body Mass Index
CAD	Coronary artery disease
cDNA	Complementary DNA
CIMT	Carotid intima-media thickness
Col II	Collagen type II
COX-2	Cyclooxygenase-2
CRP	C-reactive protein
DPP4	Dipeptidyl peptidase-4 inhibitors
EC	Endothelial cell
ELISA	Enzyme-linked immunoassay
eNOS	Endothelial nitric oxide synthase
FDA	Food and Drug Administration
FFAs	Free fatty acids
GAD	Glutamic acid decarboxylase
GDM	Gestational diabetes mellitus
GLP-1	Glucagon-like peptide-1
GLUT4	Glucose transporter type 4
HAPO	Hyperglycemia and Adverse Pregnancy Outcomes
HDL	High-density lipoprotein
HLA-G	Human leukocyte antigen-G
HOMA	Homeostasis model assessment of insulin resistance

IAA	Insulin autoantibodies
IADPSG	Association of Diabetes and Pregnancy Study Group
ICAM	Intracellular adhesion molecules
IGF-1	Insulin-like growth factor
IL-6	Interleukin-6
IR	Insulin resistance
IRS	Insulin receptor substrate 1
JAK2	Janus kinase 2
JNK	C-Jun N-terminal kinases
KDa	KiloDalton
LDL	Low density lipoprotein cholesterol
Mac	Macrophage
MCP-1	Monocyte chemoattractant protein 1
MMP	Matrix metalloproteinases
MODY	Maturity-onset diabetes of the young
mTOR	mammalian target of rapamycin
NAFLD	Nonalcoholic fatty liver disease
NDDG	Carpenter-Coustan and National Diabetes Data Group
NF- κ B	Nuclear factor- κ B
NGT	Normal glucose tolerance
NICE	National Institute for Health and Care Excellence
NO	Nitric oxide
NPH	Neutral protamine Hagedorn
OA	Osteoarthritis
OD	Optical density
OGTT	Oral glucose tolerance test
OSAS	Obstructive sleep apnoea syndrome
PCOD	Polycystic Ovary Disease

PED	Pre-existing diabetes
PIP3	Phosphoinositol-3, 4, 5-phosphate
PKC	protein kinase C
PPAR γ	Peroxisome proliferator-activated receptors
ROC	Receiver operating characteristic
SMCs	Smooth muscle cells
STAT3	Signal transducer and activator of transcription 3
T1DM	Type 1 diabetes mellitus
T2DM	Type 2 diabetes mellitus
TC	Total Cholesterol
TG	Triglycerides
TNF- α	Tumor necrosis factor- α
VCAM	vascular adhesion molecules
VEGF	vascular endothelial growth factor
WHO	World Health Organization

ABSTRACT

Background: Omentin-1 a new anti-inflammatory adipokine has been identified as a major visceral (omental) secretory adipokine which plays important roles in glucose homeostasis, lipid metabolism, insulin resistance and diabetes. The aim of our study was to evaluate serum omentin-1 levels in Gestational diabetes and assess its relation with glycemic control, insulin resistance and metabolic parameters. **Patients and Methods:** The study included 25 women with gestional diabetes was diagnosed according to the WHO 2013 criteria, 25 pregnant women with normal glucose tolerance and 25 healthy non pregnant female of matched age as a control group. They were subjected to full history taking and clinical examination. Fasting (blood glucose, insulin, lipid profile, and omentin-1) and 2 hour Oral glucose tolerance test with 75g glucose were measured. HOMA-IR was calculated. Data was analyzed and expressed in terms of mean \pm SD. Pearson correlation was performed to study the correlation of serum omentin-1 in relation to glycemic control, insulin resistance and metabolic parameters in the studied groups. **Conclusion:** Serum Omentin was negatively correlated with fasting insulin level and HOMA-IR both in cases and in patient group. This suggests that Omentin has a role in insulin resistance. There was a high significant negative correlation between Omentin and glycemic control, total cholesterol, triglyceride and LDL (P value <0.01) and high significant positive correlation between Omentin and HDL (P value <0.01) in all studied groups. The best cut off point of serum omentin was 177.8 ng/ml to differentiate cases from controls using ROC curve analysis.

INTRODUCTION

INTRODUCTION

Gestational diabetes is carbohydrate intolerance of varied severity that begins or is first recognized during pregnancy, can affect up to 16–20% of all pregnancies (*Bianchi et al., 2017*).

In the WHO 2013 diagnostic criteria, Gestational diabetes mellitus (GDM) should be diagnosed at any time in pregnancy if one or more of the following abnormality are met, fasting plasma glucose 92 – 125 mg/dl (5.1 – 6.9 mmol/l), one hour plasma glucose ≥ 180 mg/dl (10mmol/l), 2-hour glucose 153-199 mg/dl (8.5 -11 mmol/l) after overnight fasting with 75g glucose load (*Thomas and Duarte-Gardea, 2017*).

Skeletal muscle is the principal site of whole-body glucose disposal, and along with adipose tissue, becomes severely insulin resistant during the latter half of pregnancy. Normal pregnancy is characterized by a ~50% decrease in insulin-mediated glucose disposal in humans and a 200–250% increase in insulin secretion to maintain euglycemia in the mother (*Qiao et al., 2017*).

GDM is caused by an imbalance between insulin resistance and insulin secretion during pregnancy which, historically, has been thought to occur when the pancreatic β cells fail to keep pace with the increasing insulin resistance that occurs during the second half of pregnancy (*McCabe and Perng, 2017*).

Pregnant women with GDM increased risk of adverse pregnancy and infant outcomes, and in the long-term, they increase the risk of developing obesity, type 2 diabetes and cardiovascular disease in both the mother and child (*Pang et al., 2017*).

INTRODUCTION

Omentin is a 38-40 kDa adipokine which was identified from complementary DNA (cDNA) library in visceral omental adipose tissue (*Escoté et al., 2017*).

There are two omentin genes, located adjacent to each other in the 1q22–q23 chromosomal region, which produce omentin-1 and omentin-2. Both isoforms show different pattern of tissue expression. In humans, omentin-1 is the predominant isoform in plasma and adipose tissue (*Schleinitz, 2019*).

Omentin is a putative insulin sensitiser, while omentin concentrations are decreased in some insulin resistant states, such as polycystic ovary syndrome, and are down regulated by insulin and glucose (*Delitala et al., 2017*).

The biological function(s) of omentin-1 in human pregnancy is not known, but it may have a role in regulating blood glucose levels; it enhances insulin-stimulated glucose uptake in human subcutaneous and visceral adipocytes (*Dong et al., 2017*).

Maternal omentin-1 levels are higher in the first trimester to both the second trimester and the non-pregnant state. Higher omentin-1 in the first trimester of pregnancy may be due to increased fat accretion or reduced secretion from maternal adipose tissue later in pregnancy (*Houldsworth et al., 2017*).

Aim of the work

Aim of the work

The aim of the study is to assess the relation between serum Omentin and insulin resistance in Gestational diabetes.

Review of literature
